KRT33B and glioblastoma: GGT6 expression is downregulated in low‐grade gliomas (LGG), which has significant prognostic value and can be used as a potential early detection biomarker. In combination with KRT33B and KRT75, it can improve the prediction of LGG, glioblastoma (GBM) and LGG to GBM transformed tumors [41].